Please use this identifier to cite or link to this item: http://hdl.handle.net/10603/4564
Title: Synthesis and characterization of (-)Galanthamine hydrobromide and memantine hydrochloride as anti Alzheimers drugs and their impurities
Researcher: Reddy, Jambula Mukunda
Guide(s): Reddy, G Mahesh
Himabindu, V
Keywords: Alzheimer?s Disease
Galanthamine hydrobromide
Memantine hydrochloride
Chemistry
Upload Date: 5-Sep-2012
University: Jawaharlal Nehru Technological University
Completed Date: May, 2011
Abstract: Chapter-I deals with the introduction to Alzheimer?s disease, biological importance of (-)-Galanthamine, Memantine and the previous synthetic approaches cited in the literature towards the synthesis of racemic.Galanthamine 1. In chapter-II, studies towards the total synthesis of (-) Galanthamine and its hydro bromide salt is described, wherein a stereo selective reduction of prochiral ketone using L-selectride followed by diastereomeric separation using di-p-toluyl-D-tartaric acid. Synthesis and characterization of Galanthamine process related chiral impurities have been described in chapter-III. A detailed study on polymorphism of Galanthamine amorphous and crystalline forms is presented in chapter-IV. An improved, cost effective and scalable process has been developed for Memantine hydrochloride. CHAPTER-I This chapter deals with the introduction to Alzheimer?s disease, biological importance of (-)-Galanthamine and the previous synthetic approaches cited in the literature towards the synthesis of racemic and (-) Galanthamine 1. CHAPTER-II This chapter describes the studies towards the total synthesis of (-) Galanthamine and its hydrobromide salt, through a stereo selective reduction of prochiral ketone using L-selectride followed by diasteromeric separation using p-diparatoluyl-D-tartaric acid. CHAPTER- III Synthesis and characterization of Galanthamine process related chiral impurities have been described in chapter-III. Impurities are in pharmaceutical industry are the unwanted chemicals that remain with the active pharmaceutical ingredients (API?s) or developed during synthesis of API or in formulation. Various regulatory authorities like ICH, USFDA, Canadian Drug and Health agency are emphasizing on the purity requirements and the identification of impurities in API?s. Formation of impurities due to incomplete chemical reactions, Impurities originating from impurities in the starting material of the synthesis.
Pagination: 106p.
URI: http://hdl.handle.net/10603/4564
Appears in Departments:Department of Chemistry

Files in This Item:
File Description SizeFormat 
01_title.pdfAttached File86.93 kBAdobe PDFView/Open
02_dedication.pdf159.91 kBAdobe PDFView/Open
03_declaration.pdf97.12 kBAdobe PDFView/Open
04_certificates.pdf133.8 kBAdobe PDFView/Open
05_acknowledgements.pdf160.93 kBAdobe PDFView/Open
06_abstract.pdf265.43 kBAdobe PDFView/Open
07_abbreviations.pdf171.11 kBAdobe PDFView/Open
08_contents.pdf149.99 kBAdobe PDFView/Open
09_list of charts and figures.pdf125.29 kBAdobe PDFView/Open
10_chapter 1.pdf381.82 kBAdobe PDFView/Open
11_chapter 2.pdf911.73 kBAdobe PDFView/Open
12_chapter 3.pdf818.8 kBAdobe PDFView/Open
13_chapter 4.pdf231.18 kBAdobe PDFView/Open
14_chapter 5.pdf459.23 kBAdobe PDFView/Open
15_conclusion.pdf50.83 kBAdobe PDFView/Open
16_publications.pdf165.12 kBAdobe PDFView/Open
17_spectral data.pdf5.48 MBAdobe PDFView/Open


Items in Shodhganga are protected by copyright, with all rights reserved, unless otherwise indicated.

Altmetric Badge: